Racial Variation in the Cost-Effectiveness of Chemotherapy for Prostate Cancer
- 1 May 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 7 (3S) , e16s-e24s
Abstract
The likelihood of chemotherapy being cost-effective for patients with metastatic prostate cancer differs across racial subgroups. This uncertainty presents challenges for managed-care decision makers.Keywords
This publication has 33 references indexed in Scilit:
- The Potential Impact Of Comparative Effectiveness Research On The Health Of Minority PopulationsHealth Affairs, 2010
- Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposalTrials, 2010
- Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part IIIValue in Health, 2009
- Race, healthcare access and physician trust among prostate cancer patientsCancer Causes & Control, 2009
- Dealing with heterogeneity of treatment effects: is the literature up to the challenge?Trials, 2009
- Prostate cancer chemotherapy in the era of targeted therapyProstate Cancer and Prostatic Diseases, 2008
- Reducing Cancer Disparities for Minorities: A Multidisciplinary Research Agenda to Improve Patient Access to Health Systems, Clinical Trials, and Effective Cancer TherapyJournal of Clinical Oncology, 2006
- Approval SummaryClinical Cancer Research, 2004
- Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare DataMedical Care, 2002
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983